Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma [Sarcomas]

Conclusion
Selinexor was well tolerated at a 60-mg flat dose on a 3-weeks-on, 1-week-off schedule. There was no clinically meaningful impact of food on PKs. Preliminary evidence of anticancer activity in sarcoma was demonstrated.

Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Gounder, Zer, Tap, Salah, Dickson, Gupta, Keohan, Loong, DAngelo, Baker, Condy, Nyquist-Schultz, Tanner, Erinjeri, Jasmine, Friedlander, Carlson, Unger, Saint-Martin, Rashal, Ellis, Kauffman, Shacham, Schwartz, Abdul Razak Tags: Phase I and Clinical Pharmacology, Osteosarcoma & Ewing Sarcomas:, Rhabdo & Other Soft Tissue Sarcomas: Source Type: research